image
Healthcare - Medical - Healthcare Information Services - NYSE - US
$ 61.69
4.01 %
$ 11.6 B
Market Cap
55.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DOCS stock under the worst case scenario is HIDDEN Compared to the current market price of 61.7 USD, Doximity, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DOCS stock under the base case scenario is HIDDEN Compared to the current market price of 61.7 USD, Doximity, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DOCS stock under the best case scenario is HIDDEN Compared to the current market price of 61.7 USD, Doximity, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DOCS

image
$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
570 M REVENUE
19.98%
228 M OPERATING INCOME
39.01%
223 M NET INCOME
51.23%
273 M OPERATING CASH FLOW
48.44%
-29.3 M INVESTING CASH FLOW
-93.95%
-131 M FINANCING CASH FLOW
52.58%
138 M REVENUE
-17.98%
48.7 M OPERATING INCOME
-39.09%
62.5 M NET INCOME
-16.94%
98.5 M OPERATING CASH FLOW
51.08%
-24.5 M INVESTING CASH FLOW
58.47%
-29.7 M FINANCING CASH FLOW
-17.54%
Balance Sheet Doximity, Inc.
image
Current Assets 1.09 B
Cash & Short-Term Investments 916 M
Receivables 128 M
Other Current Assets 44.6 M
Non-Current Assets 176 M
Long-Term Investments 0
PP&E 22.5 M
Other Non-Current Assets 153 M
72.42 %10.15 %3.53 %12.11 %Total Assets$1.3b
Current Liabilities 156 M
Accounts Payable 1.36 M
Short-Term Debt 2.21 M
Other Current Liabilities 153 M
Non-Current Liabilities 25.4 M
Long-Term Debt 10.2 M
Other Non-Current Liabilities 15.2 M
84.04 %5.61 %8.39 %Total Liabilities$181.7m
EFFICIENCY
Earnings Waterfall Doximity, Inc.
image
Revenue 570 M
Cost Of Revenue 55.9 M
Gross Profit 515 M
Operating Expenses 287 M
Operating Income 228 M
Other Expenses 4.62 M
Net Income 223 M
600m600m500m500m400m400m300m300m200m200m100m100m00570m(56m)515m(287m)228m(5m)223mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
90.20% GROSS MARGIN
90.20%
39.94% OPERATING MARGIN
39.94%
39.13% NET MARGIN
39.13%
20.62% ROE
20.62%
17.65% ROA
17.65%
17.37% ROIC
17.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Doximity, Inc.
image
300m300m250m250m200m200m150m150m100m100m50m50m00202020202021202120222022202320232024202420252025
Net Income 223 M
Depreciation & Amortization -996 K
Capital Expenditures 0
Stock-Based Compensation 72.4 M
Change in Working Capital 0
Others 0
Free Cash Flow 273 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Doximity, Inc.
image
Wall Street analysts predict an average 1-year price target for DOCS of $52.9 , with forecasts ranging from a low of $38 to a high of $70 .
DOCS Lowest Price Target Wall Street Target
38 USD -38.40%
DOCS Average Price Target Wall Street Target
52.9 USD -14.32%
DOCS Highest Price Target Wall Street Target
70 USD 13.47%
Price
Max Price Target
Min Price Target
Average Price Target
90908080707060605050404030302020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Doximity, Inc.
image
Sold
0-3 MONTHS
7.62 M USD 4
3-6 MONTHS
88 M USD 6
6-9 MONTHS
6.79 M USD 3
9-12 MONTHS
3.67 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Doximity Crushes The Rule Of 40 - Try Rule Of 58 I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation. seekingalpha.com - 1 week ago
Doximity (DOCS) Laps the Stock Market: Here's Why Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close. zacks.com - 1 week ago
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot? DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots. zacks.com - 2 weeks ago
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS? DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage. zacks.com - 2 weeks ago
DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health? DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge. zacks.com - 3 weeks ago
Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy' I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook. seekingalpha.com - 3 weeks ago
OGN or DOCS: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 3 weeks ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. globenewswire.com - 4 weeks ago
DOCS Boosts Client Retention via Workflow Integration and AI Tools Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals. zacks.com - 4 weeks ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm NEW YORK , June 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company's business and operations. prnewswire.com - 1 month ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. globenewswire.com - 1 month ago
Doximity Declines 4.4% in a Month: How to Play the Stock Now? Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EBITDA margin. For fiscal 2025, revenues totaled $570.4 million, up 20% year over year, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55%. zacks.com - 1 month ago
8. Profile Summary

Doximity, Inc. DOCS

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 11.6 B
Dividend Yield 0.00%
Description Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact 500, 3rd Street, San Francisco, CA, 94107 https://www.doximity.com
IPO Date June 24, 2021
Employees 827
Officers Mr. Jeffrey A. Tangney Co-Founder, Chief Executive Officer & Chairperson Mr. Jey Balachandran Chief Technology Officer Dr. Nate Gross M.D. Co-Founder & Chief Strategy Officer Ms. Shari Buck Co-founder and SVice President People & Ops Mr. Perry Scott Gold Head of Investor Relations Mr. Bruno Miranda Senior Vice President of Engineering Ms. Anna Bryson Chief Financial Officer Ms. Jennifer W. Chaloemtiarana J.D. General Counsel & Corporate Secretary Mr. Craig A. Overpeck Senior Vice President of Commercial Operations Mr. Joel Davis Senior Vice President of Product